Cargando…

A Monoclonal Antibody, KM10 Reactive with Human Gastrointestinal Cancer and Its Application for Immunotherapy

A monoclonal antibody, KM10 (IgG(1)) was produced by fusing spleen cells from a human gastric cancer cell (MKN45)‐primed BALB/c mouse with the murine myeloma cell line X63‐Ag8‐653. The antibody reacted strongly with the plasma membrane of human gastrointestinal carcinoma. Sections of the malignant a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohyanagi, Harumasa, Ishida, Hidefumi, Ishida, Tsuneyuki, Soyama, Nobuhiko, Yamamoto, Masahiro, Okumura, Shuichi, Kano, Yoshiaki, Ueda, Yasuo, Saitoh, Yoichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 1988
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917666/
https://www.ncbi.nlm.nih.gov/pubmed/3148606
http://dx.doi.org/10.1111/j.1349-7006.1988.tb01566.x
_version_ 1783317261236305920
author Ohyanagi, Harumasa
Ishida, Hidefumi
Ishida, Tsuneyuki
Soyama, Nobuhiko
Yamamoto, Masahiro
Okumura, Shuichi
Kano, Yoshiaki
Ueda, Yasuo
Saitoh, Yoichi
author_facet Ohyanagi, Harumasa
Ishida, Hidefumi
Ishida, Tsuneyuki
Soyama, Nobuhiko
Yamamoto, Masahiro
Okumura, Shuichi
Kano, Yoshiaki
Ueda, Yasuo
Saitoh, Yoichi
author_sort Ohyanagi, Harumasa
collection PubMed
description A monoclonal antibody, KM10 (IgG(1)) was produced by fusing spleen cells from a human gastric cancer cell (MKN45)‐primed BALB/c mouse with the murine myeloma cell line X63‐Ag8‐653. The antibody reacted strongly with the plasma membrane of human gastrointestinal carcinoma. Sections of the malignant and benign tissues were tested with immunoperoxidase. All of 10 (100%) large intestinal cancers, 26 of 31 (84%) gastric cancers, 5 of 7 (71%) pancreatic cancers and all of 3 (100%) ampullary cancers reacted positively. Moderate or weak reactivity was observed with normal human tissues, hepatoma and carcinomas of mammary, thyroid and adrenal glands. According to a study of the distribution of (125)I‐labeled KM10 in nude mice bearing human gastric cancer, KM10 selectively localized in tumor tissue rather than normal tissue. Whole body autoradiography also supported such a selective distribution. Destruction of antigenic properties by pronase digestion demonstrated its protein nature and by Western blot analysis, it was identified as a protein with an Mr of 180–200 kd. KM10‐adriamycin (ADM) conjugate was prepared via an oxidized dextran bridge and this immunoconjugate retained the binding activity against human gastric cancer. MKN45 cells were inoculated subcutaneously into athymic mice and intravenous treatment was begun when the tumor became measurable. A dose‐dependent antitnmor activity was observed in vivo with KM10‐ADM conjugate, while this conjugate was less toxic than free ADM.
format Online
Article
Text
id pubmed-5917666
institution National Center for Biotechnology Information
language English
publishDate 1988
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-59176662018-05-11 A Monoclonal Antibody, KM10 Reactive with Human Gastrointestinal Cancer and Its Application for Immunotherapy Ohyanagi, Harumasa Ishida, Hidefumi Ishida, Tsuneyuki Soyama, Nobuhiko Yamamoto, Masahiro Okumura, Shuichi Kano, Yoshiaki Ueda, Yasuo Saitoh, Yoichi Jpn J Cancer Res Article A monoclonal antibody, KM10 (IgG(1)) was produced by fusing spleen cells from a human gastric cancer cell (MKN45)‐primed BALB/c mouse with the murine myeloma cell line X63‐Ag8‐653. The antibody reacted strongly with the plasma membrane of human gastrointestinal carcinoma. Sections of the malignant and benign tissues were tested with immunoperoxidase. All of 10 (100%) large intestinal cancers, 26 of 31 (84%) gastric cancers, 5 of 7 (71%) pancreatic cancers and all of 3 (100%) ampullary cancers reacted positively. Moderate or weak reactivity was observed with normal human tissues, hepatoma and carcinomas of mammary, thyroid and adrenal glands. According to a study of the distribution of (125)I‐labeled KM10 in nude mice bearing human gastric cancer, KM10 selectively localized in tumor tissue rather than normal tissue. Whole body autoradiography also supported such a selective distribution. Destruction of antigenic properties by pronase digestion demonstrated its protein nature and by Western blot analysis, it was identified as a protein with an Mr of 180–200 kd. KM10‐adriamycin (ADM) conjugate was prepared via an oxidized dextran bridge and this immunoconjugate retained the binding activity against human gastric cancer. MKN45 cells were inoculated subcutaneously into athymic mice and intravenous treatment was begun when the tumor became measurable. A dose‐dependent antitnmor activity was observed in vivo with KM10‐ADM conjugate, while this conjugate was less toxic than free ADM. Blackwell Publishing Ltd 1988-12 /pmc/articles/PMC5917666/ /pubmed/3148606 http://dx.doi.org/10.1111/j.1349-7006.1988.tb01566.x Text en
spellingShingle Article
Ohyanagi, Harumasa
Ishida, Hidefumi
Ishida, Tsuneyuki
Soyama, Nobuhiko
Yamamoto, Masahiro
Okumura, Shuichi
Kano, Yoshiaki
Ueda, Yasuo
Saitoh, Yoichi
A Monoclonal Antibody, KM10 Reactive with Human Gastrointestinal Cancer and Its Application for Immunotherapy
title A Monoclonal Antibody, KM10 Reactive with Human Gastrointestinal Cancer and Its Application for Immunotherapy
title_full A Monoclonal Antibody, KM10 Reactive with Human Gastrointestinal Cancer and Its Application for Immunotherapy
title_fullStr A Monoclonal Antibody, KM10 Reactive with Human Gastrointestinal Cancer and Its Application for Immunotherapy
title_full_unstemmed A Monoclonal Antibody, KM10 Reactive with Human Gastrointestinal Cancer and Its Application for Immunotherapy
title_short A Monoclonal Antibody, KM10 Reactive with Human Gastrointestinal Cancer and Its Application for Immunotherapy
title_sort monoclonal antibody, km10 reactive with human gastrointestinal cancer and its application for immunotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917666/
https://www.ncbi.nlm.nih.gov/pubmed/3148606
http://dx.doi.org/10.1111/j.1349-7006.1988.tb01566.x
work_keys_str_mv AT ohyanagiharumasa amonoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy
AT ishidahidefumi amonoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy
AT ishidatsuneyuki amonoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy
AT soyamanobuhiko amonoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy
AT yamamotomasahiro amonoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy
AT okumurashuichi amonoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy
AT kanoyoshiaki amonoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy
AT uedayasuo amonoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy
AT saitohyoichi amonoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy
AT ohyanagiharumasa monoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy
AT ishidahidefumi monoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy
AT ishidatsuneyuki monoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy
AT soyamanobuhiko monoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy
AT yamamotomasahiro monoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy
AT okumurashuichi monoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy
AT kanoyoshiaki monoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy
AT uedayasuo monoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy
AT saitohyoichi monoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy